FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 336:1676-1677 June 5, 1997 Number 23 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Singh, S. N. Related Article by Moss, A. J. PubMed Citation

To the Editor: In their report on the Multicenter Automatic Defibrillator Implantation Trial (MADIT), Moss et al. (Dec. 26 issue)¹ note the lower mortality in a group of patients receiving implantable defibrillators for unsustained ventricular tachycardia after myocardial infarction. However, the effect of the prophylactic use of defibrillators may have been confounded by other important differences between the two treatment groups. Beta-adrenergic antagonists are known to provide a benefit after myocardial infarction,² and their more frequent use in the defibrillator group at the time of the last contact (27 percent, as compared with 5 percent in the conventional-therapy group) would . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.